Cargando…

Comparison of Rifamycins for Efficacy Against Mycobacterium avium Complex and Resistance Emergence in the Hollow Fiber Model System

Rifamycins are integral part of the combination regimen for treatment of pulmonary Mycobacterium avium-complex [MAC] infection, but different practitioners prefer different rifamycins. The objective of the study was to compare microbial kill and resistance emergence of rifamycins using principles of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boorgula, Gunavanthi D., Jakkula, Laxmi U. M. R., Gumbo, Tawanda, Jung, Bockgie, Srivastava, Shashikant
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085489/ https://www.ncbi.nlm.nih.gov/pubmed/33935740 http://dx.doi.org/10.3389/fphar.2021.645264

Ejemplares similares

Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
por: Srivastava, Shashikant, et al.
Publicado: (2022)

Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases
por: Deshpande, Devyani, et al.
Publicado: (2016)

Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses
por: Chapagain, Moti, et al.
Publicado: (2022)

1697. Dose-response Studies of the Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Epetraborole, in the Intracellular Hollow Fiber System Model of Mycobacterium avium complex Lung Disease
por: Chapagain, Moti, et al.
Publicado: (2022)

Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence
por: Pasipanodya, Jotam G., et al.
Publicado: (2017)

Comment on “Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections”
por: Srivastava, Shashikant, et al.
Publicado: (2023)

Safety and tolerability of long-term use of omadacycline in the treatment of Mycobacterium abscessus infections
por: Srivastava, Shashikant, et al.
Publicado: (2023)

Minocycline intra-bacterial pharmacokinetic hysteresis as a basis for pharmacologic memory and a backbone for once-a-week pan-tuberculosis therapy
por: Deshpande, Devyani, et al.
Publicado: (2022)

Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary Mycobacterium kansasii
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Effect of specimen processing, growth supplement, and different metabolic population on Mycobacterium tuberculosis laboratory diagnosis
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Rifamycin O, An Alternative Anti-Mycobacterium abscessus Agent
por: Hanh, Bui Thi Bich, et al.
Publicado: (2020)

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies
por: Srivastava, Shashikant, et al.
Publicado: (2016)

1659. Pharmacokinetics/pharmacodynamics of the Novel Gyrase Inhibitor SPR719/SPR720 and Clinical Dose Selection to Treat Pulmonary Mycobacterium avium-complex Disease
por: Deshpande, Devyani, et al.
Publicado: (2020)

Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration
por: Gumbo, Tawanda, et al.
Publicado: (2021)

Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development
por: Gumbo, Tawanda, et al.
Publicado: (2023)

Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic Study
por: Zentner, Isaac, et al.
Publicado: (2020)

Comparison of Rifabutin-Based Versus Rifampin-Based Regimens for the Treatment of Mycobacterium avium Complex: A meta-Analysis Study
por: Hajikhani, Bahareh, et al.
Publicado: (2021)

C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus
por: Paulowski, Laura, et al.
Publicado: (2022)

Consolidations in Nodular Bronchiectatic Mycobacterium Avium Complex Lung Disease: Mycobacterium Avium Complex or Other Infection?
por: Im, Soo Ah, et al.
Publicado: (2010)

Characterization of the Rifamycin-Degrading Monooxygenase From Rifamycin Producers Implicating Its Involvement in Saliniketal Biosynthesis
por: Zheng, Xiao-Fu, et al.
Publicado: (2020)

Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments
por: Kumar, Kartik, et al.
Publicado: (2022)

Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Mallikaarjun, Suresh, et al.
Publicado: (2020)

Deciphering the late steps of rifamycin biosynthesis
por: Qi, Feifei, et al.
Publicado: (2018)

Treatment of Mycobacterium avium Complex Pulmonary Disease
por: Kwon, Yong-Soo, et al.
Publicado: (2019)

Mycobacterium avium complex: An unusual cause of hypercalcemia
por: Chatterjee, Tulika, et al.
Publicado: (2021)

Role of Clofazimine in Treatment of Mycobacterium avium Complex
por: Nasiri, Mohammad Javad, et al.
Publicado: (2021)

Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus
por: Ganapathy, Uday S., et al.
Publicado: (2021)

A tale of two images: From mycobacterium avium complex-lung disease (MAC-LD) to mycobacterium avium complex-pleural disease()
por: Varkey, Mary Rithu, et al.
Publicado: (2021)

Study on Dissolution Thermodynamics and Cooling Crystallization of Rifamycin S
por: Chen, Kui, et al.
Publicado: (2021)

Mycobacterium avium complex enteritis in HIV-infected patient
por: Ishikane, Masahiro, et al.
Publicado: (2014)

Mycobacterium avium complex: Adherence as a way of life
por: Falkinham, Joseph O.
Publicado: (2018)

Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management
por: Daley, Charles L, et al.
Publicado: (2020)

Adenocarcinoma of the lung with concurrent Mycobacterium avium complex infection
por: Walker, Christopher M, et al.
Publicado: (2021)

Pleuroparenchymal fibroelastosis in mycobacterium avium complex lung disease
por: Sugino, Keishi, et al.
Publicado: (2023)

1899. Core Outcome Domains for Mycobacterium avium complex Pulmonary Disease Clinical Trials: Mycobacterium avium complex Core Outcomes Research (MACCOR)
por: Varley, Cara D, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8n47sr5kgk7cgpd0fkatfm9l59